Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bone-Saving drug may shield patients after bariatric surgery

NCT ID NCT04742010

Prevention Sponsor: Stinus Gadegaard Hansen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single infusion of zoledronic acid can prevent bone and muscle loss in adults aged 35 and older who are undergoing bariatric surgery. Fifty-nine participants were randomly assigned to receive either the drug or a placebo. The main goal was to measure changes in spine bone density using a special CT scan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

59 people

The number who actually took part.

Started

Feb 2021

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 35 years old or older * Eligible for bariatric surgery (BMI\>35 kg/m2 with obesity-related comorbidity) Exclusion Criteria: * Pregnancy or breastfeeding. * Chronic kidney disease with estimated GFR\<45 ml/min. * Hypocalcemia . * Hypersensitivity to bisphosphonates, mannitol, sodium citrate or water. * Metabolic bone disease (osteoporosis is allowed). * Prior treatment with anti-osteoporotic agents. * Treatment with oral glucocorticoids * Other diseases with known effects on bone metabolism

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bariatric surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic muscular atrophy obesity disorder osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bariatric surgery Bone loss Muscle atrophy

Contacts and locations

Locations

  • Hospital South West Jutland

    Esbjerg, 6700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.